These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

847 related articles for article (PubMed ID: 33899130)

  • 61. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
    Pehlivan KC; Duncan BB; Lee DW
    Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
    [TBL] [Abstract][Full Text] [Related]  

  • 62. CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial.
    Cordoba S; Onuoha S; Thomas S; Pignataro DS; Hough R; Ghorashian S; Vora A; Bonney D; Veys P; Rao K; Lucchini G; Chiesa R; Chu J; Clark L; Fung MM; Smith K; Peticone C; Al-Hajj M; Baldan V; Ferrari M; Srivastava S; Jha R; Arce Vargas F; Duffy K; Day W; Virgo P; Wheeler L; Hancock J; Farzaneh F; Domning S; Zhang Y; Khokhar NZ; Peddareddigari VGR; Wynn R; Pule M; Amrolia PJ
    Nat Med; 2021 Oct; 27(10):1797-1805. PubMed ID: 34642489
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effect of anti-CD19 chimeric antigen receptor T cell therapy in children with relapsed or refractory acute B-lymphocytic leukemia and its prognosis.
    Li N; Li H
    J BUON; 2021; 26(1):159-165. PubMed ID: 33721447
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.
    Liu S; Deng B; Yin Z; Lin Y; An L; Liu D; Pan J; Yu X; Chen B; Wu T; Chang AH; Tong C
    Am J Hematol; 2021 Jun; 96(6):671-679. PubMed ID: 33725422
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Efficacy and safety of CD19 CAR-T cell therapy for patients with B cell acute lymphoblastic leukemia involving extramedullary relapse.
    Huang L; Zhang M; Wei G; Zhao H; Hu Y; Huang H
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):151-159. PubMed ID: 36161297
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
    Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
    Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
    [TBL] [Abstract][Full Text] [Related]  

  • 67. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.
    Shah BD; Ghobadi A; Oluwole OO; Logan AC; Boissel N; Cassaday RD; Leguay T; Bishop MR; Topp MS; Tzachanis D; O'Dwyer KM; Arellano ML; Lin Y; Baer MR; Schiller GJ; Park JH; Subklewe M; Abedi M; Minnema MC; Wierda WG; DeAngelo DJ; Stiff P; Jeyakumar D; Feng C; Dong J; Shen T; Milletti F; Rossi JM; Vezan R; Masouleh BK; Houot R
    Lancet; 2021 Aug; 398(10299):491-502. PubMed ID: 34097852
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
    Cappell KM; Sherry RM; Yang JC; Goff SL; Vanasse DA; McIntyre L; Rosenberg SA; Kochenderfer JN
    J Clin Oncol; 2020 Nov; 38(32):3805-3815. PubMed ID: 33021872
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia.
    Cao J; Wang G; Cheng H; Wei C; Qi K; Sang W; Zhenyu L; Shi M; Li H; Qiao J; Pan B; Zhao J; Wu Q; Zeng L; Niu M; Jing G; Zheng J; Xu K
    Am J Hematol; 2018 Jul; 93(7):851-858. PubMed ID: 29633386
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies.
    Xu X; Sun Q; Liang X; Chen Z; Zhang X; Zhou X; Li M; Tu H; Liu Y; Tu S; Li Y
    Front Immunol; 2019; 10():2664. PubMed ID: 31798590
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL.
    Qi Y; Zhao M; Hu Y; Wang Y; Li P; Cao J; Shi M; Tan J; Zhang M; Xiao X; Xia J; Ma S; Qiao J; Yan Z; Li H; Pan B; Sang W; Li D; Li Z; Zhou J; Huang H; Liang A; Zheng J; Xu K
    Blood; 2022 Jun; 139(23):3376-3386. PubMed ID: 35338773
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Advances in the development of chimeric antigen receptor-T-cell therapy in B-cell acute lymphoblastic leukemia.
    Zhang X; Li JJ; Lu PH
    Chin Med J (Engl); 2020 Feb; 133(4):474-482. PubMed ID: 31977556
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Anti-CD19 CAR T-cell consolidation therapy combined with CD19+ feeding T cells and TKI for Ph+ acute lymphoblastic leukemia.
    Chen LY; Gong WJ; Li MH; Zhou HX; Xu MZ; Qian CS; Kang LQ; Xu N; Yu Z; Qiao M; Zhang TT; Zhang L; Tian ZL; Sun AN; Yu L; Wu DP; Xue SL
    Blood Adv; 2023 Sep; 7(17):4913-4925. PubMed ID: 36897251
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Long-term follow-up of humanized and murine CD19 CAR-T-cell therapy for B-cell acute lymphoblastic leukemia].
    Du MY; Zhang YQ; Liao DY; Xie W; Xiong W; Mei H; Hu Y
    Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):793-799. PubMed ID: 38049329
    [No Abstract]   [Full Text] [Related]  

  • 75. Effect of transplant status in CD19-targeted CAR T-cell therapy: a systematic review and meta-analysis.
    Nagle K; Tafuto B; Palladino Kim L; Parrott JS
    Med Oncol; 2018 Sep; 35(11):144. PubMed ID: 30206753
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
    Gauthier J; Bezerra ED; Hirayama AV; Fiorenza S; Sheih A; Chou CK; Kimble EL; Pender BS; Hawkins RM; Vakil A; Phi TD; Steinmetz RN; Jamieson AW; Bar M; Cassaday RD; Chapuis AG; Cowan AJ; Green DJ; Kiem HP; Milano F; Shadman M; Till BG; Riddell SR; Maloney DG; Turtle CJ
    Blood; 2021 Jan; 137(3):323-335. PubMed ID: 32967009
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Impact of tocilizumab on anti-CD19 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia.
    Wang X; Zhang B; Zhang Q; Zhou H; Sun Q; Zhou Y; Li T; Zhou D; Shen Z; Zhang J; Li P; Liang A; Zhou K; Han L; Hu Y; Yang Y; Cao J; Li Z; Xu K; Sang W
    Cancer; 2024 Aug; 130(15):2660-2669. PubMed ID: 38578977
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure.
    Gauthier J; Hirayama AV; Purushe J; Hay KA; Lymp J; Li DH; Yeung CCS; Sheih A; Pender BS; Hawkins RM; Vakil A; Phi TD; Steinmetz RN; Shadman M; Riddell SR; Maloney DG; Turtle CJ
    Blood; 2020 May; 135(19):1650-1660. PubMed ID: 32076701
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults.
    Gardner RA; Finney O; Annesley C; Brakke H; Summers C; Leger K; Bleakley M; Brown C; Mgebroff S; Kelly-Spratt KS; Hoglund V; Lindgren C; Oron AP; Li D; Riddell SR; Park JR; Jensen MC
    Blood; 2017 Jun; 129(25):3322-3331. PubMed ID: 28408462
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells.
    Park JH; Romero FA; Taur Y; Sadelain M; Brentjens RJ; Hohl TM; Seo SK
    Clin Infect Dis; 2018 Aug; 67(4):533-540. PubMed ID: 29481659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.